Radioiodine Therapy: Current Imaging Concepts Introduction

  • Luca Giovanella
Conference paper


The ability of thyroid and differentiated thyroid carcinoma (DTC) cells to trap and to handle iodine forms the basis of radioiodine (131I) diagnostic scanning and treatment of patients affected by primary hyperthyroidism and differentiated thyroid carcinoma, respectively. Iodine is transported and trapped within the follicular thyroid cells by the sodium iodide symporter (NIS). The NIS is a 643- amino-acid protein located in the laterobasal compartment of follicular cells closed to the capillaries. Iodine trapping is achieved by an energy-dependent mechanism that, in physiologic conditions, depends mainly on thyrotropin [thyroid-stimulating hormone (TSH)] [1]. Iodine is then passively transported by the pendrin, a chlorideiodine transport protein, into the colloid across the apical membrane. Then, iodide oxidation into iodine and iodine organification into tyrosyl residues of the thyroglobulin (Tg) occur at the luminal surface of the thyrocyte apical membrane (Fig. 1) [2].


Differentiate Thyroid Cancer Differentiate Thyroid Carcinoma Radioiodine Therapy Thyroid Remnant Follicular Thyroid Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dai G, Levy O, Carrasco N (1996) Cloning and characterization of the thyroid iodine transporter. Nature 379:458–460PubMedCrossRefGoogle Scholar
  2. 2.
    Taurog A (2000) Hormone synthesis: thyroid iodine metabolism. In: Braverman LE, Utiger RD (eds) The thyroid. A fundamental and clinical text. Lippincott Williams & Wilkins, Philadelphia, pp 61–85Google Scholar
  3. 3.
    Marinelli LD, Quimbly EH, Hine GJ (1948) Dosage determination with radioactive isotopes. Practical considerations in therapy and protection. AJR Am J Roengtenol 59:260–281Google Scholar
  4. 4.
    Dietlein M, Dressler J, Joseph K et al (1999) Guideline for radioiodine therapy (RIT) in benign thyroid diseases. Nuklearmedizin 38:219–220PubMedGoogle Scholar
  5. 5.
    Giovanella L, Suriano S, Maffioli M et al (2010) (99m)Tc-sestaMIBI scanning in thyroid nodules with nondiagnostic cytology. Head Neck 32:607–611PubMedGoogle Scholar
  6. 6.
    Cooper DS, Doherty GM, Haugen BR et al (2009) Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167–1214PubMedCrossRefGoogle Scholar
  7. 7.
    Luster M, Clarke SE, Dietlein M et al (2008) Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 35:1941–1959PubMedCrossRefGoogle Scholar
  8. 8.
    Giovanella L, Suriano R, Ricci R et al (2011) Postsurgical thyroid remnant estimation by (99m)Tc-pertechnetate scintigraphy predicts radioiodine ablation effectiveness in patients with differentiated thyroid carcinoma. Head Neck 33:552–556PubMedCrossRefGoogle Scholar
  9. 9.
    Giovanella L, Suriano R, Castellani M et al (2011) Thyroid remnant estimation by Tc99m-sestaMIBI scanning predicts the effectiveness of rhTSH-stimulated I-131 ablation in patients with differentiated thyroid carcinoma. Clin Nucl Med 36:781–785PubMedCrossRefGoogle Scholar
  10. 10.
    Wong KK, Sisson JC, Koral KF et al (2010) Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT. AJR Am J Roentgenol 195:730–736PubMedCrossRefGoogle Scholar
  11. 11.
    Capoccetti F, Criscuoli B, Rossi G et al (2009) The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer. Q J Nucl Med Mol Imaging 53:536–545PubMedGoogle Scholar
  12. 12.
    Freudenberg LS, Antoch G, Frilling A et al (2008) Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET. Eur J Nucl Med Mol Imaging 35:950–957PubMedCrossRefGoogle Scholar
  13. 13.
    Briele B, Hotze AL, Kropp J et al (1991) A comparison of 201Tl and 99mTc-MIBI in the follow-up of differentiated thyroid carcinoma. Nuklearmedizin 30:115–124PubMedGoogle Scholar
  14. 14.
    Gorges R, Kahaly G, Muller-Brandt J et al (2001) Radionuclide-labeled somatostatin analogues for diagnostic and therapeutic purposes in non-medullary thyroid cancer. Thyroid 11:647–659PubMedCrossRefGoogle Scholar
  15. 15.
    Blaser D, Maschauer S, Kuwert T et al (2006) In vitro studies on the signal transduction of thyroidal uptake of 18F-FDG and 131I-iodide. J Nucl Med 47:1382–1388PubMedGoogle Scholar
  16. 16.
    Conti PS, Durski JM, Bacqai F et al (1999) Imaging of locally recurrent and metastatic thyroid cancer with positron emission tomography. Thyroid 9:797–804PubMedCrossRefGoogle Scholar
  17. 17.
    Wang W, Macapinlac H, Larson SM et al (1999) [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 84:2291–302PubMedCrossRefGoogle Scholar
  18. 18.
    Ma C, Xie J, Lou Y et al (2010) The role of TSH for 18F-FDGPET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. Eur J Endocrinol 163:177–183PubMedCrossRefGoogle Scholar
  19. 19.
    Robbins RJ, Wan Q, Grewal RK et al (2006) Real-time prognosis for metastatic thyroid carcinoma based on FDG-PET scanning. J Clin Endocrinol Metab 91:498–505PubMedCrossRefGoogle Scholar
  20. 20.
    Iagaru A, Kalinyak, Mc Dougall IR (2007) F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med 32:690–695PubMedCrossRefGoogle Scholar
  21. 21.
    Giovanella L, Ceriani L, De Palma D et al (2011) Relationship between serum thyroglobulin and 18FDG PET/CT in 131I-negative differentiated thyroid carcinomas. Head Neck doi: 10.1002/hed.21791Google Scholar

Copyright information

© Springer-Verlag Italia 2012

Authors and Affiliations

  • Luca Giovanella
    • 1
  1. 1.Nuclear Medicine and PET/CT CentreOncology Institute of Southern SwitzerlandBellinzonaSwitzerland

Personalised recommendations